EverPoint Asset Management’s Tvardi Therapeutics TVRD Stock Holding History

EverPoint Asset Management’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$4.64M	Buy	13,889 +8,333	+150%	+$2.67M	0.09%	259
2016 Q3	$1.67M	Buy	+5,556	New	+$1.2M	0.03%	355
2016 Q1	–	Sell	-25,000	Closed	-$15.2M	–	556
2015 Q4	$15.2M	Buy	25,000 +12,500	+100%	+$6.86M	0.32%	95
2015 Q3	$6.43M	Buy	12,500 +2,361	+23%	+$1.58M	0.17%	181
2015 Q2	$4.43M	Buy	+10,139	New	+$3.92M	0.08%	293

Other funds holding TVRD

RCP

Rho Capital Partners New York $20.4M AUM

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EverPoint Asset Management's TVRD Position: Q4 2016 in Review

EverPoint Asset Management increased its Tvardi Therapeutics (TVRD) stake by 150% in Q4 2016, buying an estimated $2.67M and bringing the position to 13,889 shares worth $4.64M. The position accounts for 0.09% of the portfolio, ranked #259.

EverPoint Asset Management first reported a position in TVRD in Q2 2015 and has held it in 5 quarters since. The position peaked at $15.2M in Q4 2015. 101 funds tracked by Wall St. Rank hold TVRD as of Q4 2016.

EverPoint Asset Management held 13,889 shares of Tvardi Therapeutics worth $4.64M as of Q4 2016.
EverPoint Asset Management bought 8,333 Tvardi Therapeutics shares in Q4 2016, an estimated $2.67M.
Tvardi Therapeutics made up 0.09% of EverPoint Asset Management's portfolio in Q4 2016, its #259 holding.
EverPoint Asset Management first reported a position in Tvardi Therapeutics in Q2 2015 and has held it in 5 quarters since.
EverPoint Asset Management's Tvardi Therapeutics position peaked at $15.2M in Q4 2015.
101 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.